US Stock MarketDetailed Quotes
SAGE Sage Therapeutics
- 4.850
- -0.060-1.22%
Close Nov 21 16:00 ET
- 4.850
- 0.0000.00%
Post 16:20 ET
296.69MMarket Cap-870P/E (TTM)
5.190High4.800Low1.49MVolume5.020Open4.910Pre Close7.37MTurnover3.07%Turnover RatioLossP/E (Static)61.17MShares28.26052wk High0.54P/B234.50MFloat Cap4.62052wk Low--Dividend TTM48.35MShs Float195.970Historical High--Div YieldTTM7.94%Amplitude4.620Historical Low4.959Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Sage Therapeutics Stock Forum
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
oooooo
Gapping up
$Salesforce (CRM.US)$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group (UBS.US)$ popp...
No comment yet